Refractory Cytopenia with Multilineage Dysplasia and Ring Sideroblasts
NCI Definition: A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ring sideroblasts in the bone marrow. (WHO, 2001) 
Refractory cytopenia with multilineage dysplasia and ring sideroblastss most frequently harbor alterations in SF3B1, TET2, TP53, ASXL1, and SRSF2 .
SF3B1 Mutation, SF3B1 K700E, SF3B1 Exon 15 Mutation, SF3B1 Codon 700 Missense, and SF3B1 Exon 14 Mutation are the most common alterations in refractory cytopenia with multilineage dysplasia and ring sideroblasts .
There is 1 clinical trial for refractory cytopenia with multilineage dysplasia and ring sideroblasts, of which 1 is open and 0 are completed or closed. Of the trial that contains refractory cytopenia with multilineage dysplasia and ring sideroblasts as an inclusion criterion, 1 is phase 2 (1 open).
Allogeneic hematopoietic stem cell transplantation, cyclophosphamide, and fludarabine are the most common interventions in refractory cytopenia with multilineage dysplasia and ring sideroblasts clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.